Cell & Gene Meeting on the Mesa 2026

Transformational Science Needs a Development Strategy to Match

Cell and gene therapies are expanding into new indications, geographies, and care settings. At the same time, sponsors must navigate evolving regulatory requirements, specialized manufacturing, and logistics, site readiness, long-term follow-up, and the path to commercialization. 

Success requires more than scientific expertise. It requires every part of the development ecosystem to work together. 

Syneos Health connects therapeutic expertise, regulatory, and safety leadership, advanced therapy operations and commercialization strategy to help sponsors move confidently from first-in-human studies through long-term follow-up and market readiness. 

Where Syneos Health Creates an Edge in CGT 

Build the Strategy Around the Asset 

Every cell and gene therapy program is different. We shape development strategies around each asset’s scientific profile, manufacturing model, regulatory pathway and commercial potential — focusing expertise on the decisions most critical to its success. 

Turn Complexity Into Coordinated Execution 

Manufacturers, specialty laboratories, logistics providers, technology platforms, clinical sites and regulatory stakeholders must operate as one connected ecosystem. We help sponsors coordinate these moving parts while managing specialty testing, chain of identity, chain of custody and long-term follow-up requirements. 

Prepare Sites for What Comes Next 

As advanced therapies move beyond traditional treatment centers, sites need the right infrastructure, workflows and training. We help identify, prepare and support qualified sites for increasingly complex treatment models across oncology, rare disease, autoimmune conditions, neurology and emerging indications. 

Connect Development to Future Value 

Decisions made during development shape scalability, differentiation, access and adoption. By bringing clinical and commercial thinking together earlier, we help sponsors build stronger pathways to market and long-term asset value. 

Let’s Talk About Your Next Development Decision 

Meet with our team to discuss: 

• Early-phase and asset development strategy 
• Regulatory planning and long-term follow-up 
• Clinical operations and ecosystem orchestration 
• Site and delivery readiness 
• Manufacturing and advanced therapy logistics 
• Commercialization planning and asset value 

Whether you are advancing an emerging platform or preparing an established program for its next stage, we would welcome the opportunity to explore where Syneos Health can give your program an unexpected edge.